Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The drug treatment of terminally ill patients is reviewed. The treatment of the major discomforting symptoms of degenerative diseases--pain, anxiety, nausea, vomiting and depression--is reviewed. The use of phenothiazines, anticholinergic drugs and corticosteroids is discussed. To help patients keep track of their drugs, use of a medication schedule card is recommended.
 ...
PMID:Drug therapy in terminally ill patients. 23 20

Nutritional therapy of the cancer patient by the oral route includes management of factors that may cause anorexia, attempts to modify the patient's eating behavior, and the offering of nutritional supplements to the patient. Anoretic factors for which specific strategies may be employed include taste abnormalities, pain, nausea, and depression. Modification of the patient's eating behavior involves patient education, monitoring, and feedback. Education includes nutritional instruction and instruction in favorable patterns for mealtime eating and stimulation of snack eating. Snack eating includes the use of nutritional supplements, and patient acceptance of commercially available supplements was studied. When synthetic chemically defined nutritional products were compared with milk-based product, patients preferred the milk-based product. Intercomparisons between milk-based products showed slight differences in preference ranking among these products and also differences between patients and controls in their relative order of ranking. Preference testing may be useful in assisting the health care team in selecting the optimal nutritional supplement to offer each patient.
 ...
PMID:Oral feeding in the nutritional management of the cancer patient. 26 17

A case of pelvic actinomycosis, now seen as a complication of intrauterine contraceptive devices, is reported. A 32-year old nulliparous women who had developed pain and irregular bleeding over the previous month presented initially for removal of a Dalkon shield IUD. For the previous 5 years the IUD had caused no symptoms. The Dalkon shield could not be removed, and vaginal examination revealed a tender mass in the pouch of Douglas. The patient was hospitalized for a laparoscopy and removal of the IUD under general anesthesia. Laparoscopy revealed an acute pelvic inflammatory disease (PID) with pus leaking from bilteral pyosalpinges. The IUD was removed, and the patient was treated with parenterally by administered penicillin and streptomycin for 5 days. 3 weeks later the patient was readmitted, complaining of nausea, vomiting and malaise. Clinically she was febrile, with signs of an acute abdomen. On vaginal examination, a large tender mass was palpable in the pouch of Douglas, and the blood film revealed a leukocytosis. When her condition failed to improve after treatment with penicillin and streptomycin, a laparotomy was performed. Gross PID was found with a large ruptured tubo-ovarian abscess on the right side. A total abdominal hysterectomy with bilteral salpingo-oophorectomy was performed. After the removal of the infected organs, her temperature dropped and her condition improved rapidly. Pathological findings are reported.
 ...
PMID:Pelvic actinomycosis in association with an intrauterine contraceptive device. 29 10

34 women with recurrent primary dysmenorrhea were given prescriptions for mefenamic acid and told to use it as needed for pain and cramps. 85% felt the dysmenorrhea had improved and 15 of the women said it was completely controlled. Virtually all felt it more effective than aspirin and 13 of 18 who could make a comparison considered it more effective than propoxyphene. There were 3instances of nausea or vomiting and 1 of sleepiness. A double-blind study is now underway.
 ...
PMID:Treatment of dysmenorrhea. 33 58

A single-blind, between-patient comparative study was carried out in general practice to assess the effectiveness of antacid plus antispasmodic combination tablets (240 mg dried aluminium hydroxide B.P., 144 mg magnesium hydroxide B.P.C., and 5 mg dicyclomine hydrochloride B.P.) and aluminium hydroxide B.P. tablets (500 mg) in the management of chronic dyspepsia. Twenty patients received the combination tablets and 17 the single antacid tablets. They were instructed to chew 2 tablets 3 or 4-times daily and an additional 2 tablets at night if necessary. Patients were assessed initially, and then at 2 and 4 weeks. Both preparations were effective in controlling dyspeptic symptoms. Heartburn and nausea showed an early, significantly greater (p less than 0.05) response to the combined tablet, as did night pain after 4 weeks. Tablet intake of both preparations averaged out at just under 7 tablets per day.
 ...
PMID:A comparison of an antacid plus antispasmodic combination and aluminium hydroxide in dyspepsia. 34 Jan 40

A comparative controlled study was carried out in 40 patients suffering from rheumatoid arthritis, osteoarthrosis or ankylosing spondylitis to assess the efficacy of ketoprofen and ibuprofen. Patients were allocated at random to receive either 100 mg ketoprofen twice daily or 400 mg ibuprofen 3-times daily over a period of 3 months. Subjective overall assessments of symptoms, based on rating scale scores for pain, duration of morning stiffness and inflammation, showed that there was a greater, more rapid and more sustained improvement in those patients treated with ketoprofen. Measurements of inflamed joint size and of grip strength also improved more with ketoprofen than with ibuprofen. Side-effects, notably nausea, epigastric discomfort and abdominal pain, were more frequent and severe with ketoprofen, leading to the withdrawal of 2 patients in the early stage of the trial, and were probably related to the high dosage used. Three patients receiving ibuprofen needed 7 injections of ACTH to control their symptoms.
 ...
PMID:A comparative trial of ketoprofen and ibuprofen in patients with rheumatic disease. 35 May

The efficacy and tolerance of proquazone, 900 mg, and ibuprofen, 1200 mg, were compared in a randomized, double-blind clinical trial of 6 months' duration, with 44 patients, 21 on proquazone and 23 on ibuprofen. Comparison of proquazone-treated patients with patients treated with iburofen showed a significantly better improvement , as is demonstrated by the significant differences in the Lansbury Index, in nocturnal pain, final assessment of therapeutic effect, and number of interruptions due to lack of efficacy. All differences were in favour of proquazone, proving its therapeutic superiority over ibuprofen. The side effects in the proquazone group were mainly gastrointestinal, and 2 patients broke off treatment prematurely due to diarrhoea (in one patient, lack of efficacy was a contributory cause). A third patient discontinued because of moderate nausea and dizziness. In the ibuprofen group, 4 patients discontinued because of side effects (skin eruptions, dizziness, epigastric discomfort, and one thrombocytopenia) in addition to lack of efficacy. Proquazone seems to be an effective and well tolerated anti-inflammatory analgesic.
 ...
PMID:A long-term double-blind comparative study on proquazone (Biarison) and ibuprofen in rheumatoid arthritis. 35 39

A two-week double-blind crossover study of ketoprofen, a non-steroidal antiinflammatory agent, and placebo was done in ten patients with active rheumatoid arthritis in order to obtain a preliminary efficacy estimate of this new drug. Even after only one week of treatment, joint activity was significantly reduced while other parameters of disease activity showed strong clinical trends in favour of the drug. Only one adverse reaction (mild nausea) was reported during ketoprofen therapy. At the conclusion of the double-blind study, seven patients volunteered to continue on ketoprofen to evaluate the tolerance of the drug during proptracted administration. All patients completed over twelve months of treatment. Overall, ketoprofen gave good control of pain and inflammation, gastro-intestinal disturbance was reported in a single instance and laboratory values were not adversely affected by the drug.
 ...
PMID:A double-blind crossover evaluation of ketoprofen (Orudis) and placebo in rheumatoid arthritis with assessment of long-term tolerance. 35 31

Sixty-four women with primary dysmenorrhea participated in a double-blind, parallel trial of maproxen sodium versus placebo during three menstrual cycles. Comparative measures employed to assess the efficacy of the medications included changes in pain intensity during each dysmenorrheic episode, the degree of pain relief afforded, the necessity of using a supplementary analgesic, and the extent to which medication enabled the patients to continue their daily activities unimpeded. By these measures, naproxen sodium was significantly superior as compared to the placebo. Particularly striking was the fact that of 22 naproxen sodium treated women who historically had to stay at home from work and/or in bed, only 5 remained incapacitated compared with 21 of 26 patients of the placebo group. Only 1 patient experienced side effects (nausea and hypomenorrhea) from naproxen sodium.
 ...
PMID:Naproxen sodium in dysmenorrhea. Its influence in allowing continuation of work/school activities. 36 57

Thirty six patients with active duodenal ulcers were studied in this double blind work. 19 received placebo and 17 Cimetidine: 1 gr./day. The endoscopic control after 21 days, showed healing in 81,2% of the cases treated with Cimetidine and in 22,2% of those with placebo. After 42 days of continous treatment with Cimetidine the healing of duodenal ulcers was 82,3% against 50% with placebo; the difference being highly statestically significant; p less than 0.01. The symptoms improved with Cimetidine revealing less diurnal and nocturnal pain complete disappearance of nausea and vomit and a significant decreased ingestion of alkali tablets.
 ...
PMID:[Cimetidine in the treatment of the active duodenal ulcer]. 36 63


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>